Back |
home / stock / apre / apre message board
Subject | By | Source | When |
---|---|---|---|
It's good to know they are still a | RockStarInvestor | investorshub | 01/13/2021 2:29:20 PM |
A higher price at closing charts some positive | RockStarInvestor | investorshub | 01/12/2021 5:29:35 AM |
I am hoping with the conference tomorrow that | RockStarInvestor | investorshub | 01/11/2021 3:27:20 PM |
Premarket is up. I hope it will continue | RockStarInvestor | investorshub | 01/11/2021 2:18:13 PM |
Yeah. I agree. This one attempt has allowed | RockStarInvestor | investorshub | 01/10/2021 11:35:18 PM |
Yes--I think we are on the right track | EF5$tocks | investorshub | 01/10/2021 11:01:17 PM |
I hope that others will find value as | RockStarInvestor | investorshub | 01/10/2021 8:52:15 PM |
Your my 1st message! Yeah I agree. Oversold | RockStarInvestor | investorshub | 01/10/2021 6:17:41 PM |
Hi RockStar, in $APRE at an average of | EF5$tocks | investorshub | 01/09/2021 9:45:31 PM |
Welcome! Just started this board. I am hoping | RockStarInvestor | investorshub | 01/09/2021 4:20:08 PM |
News, Short Squeeze, Breakout and More Instantly...
Aprea Therapeutics Inc. Company Name:
APRE Stock Symbol:
NASDAQ Market:
Aprea Therapeutics Inc. Website:
DOYLESTOWN, Pa., June 21, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it will host a virtual KOL...
APR-1051 is a highly selective and potentially best-in-class oral WEE1 inhibitor Phase 1 ACESOT-1051 clinical trial is evaluating APR-1051 as monotherapy treatment in patients with significant unmet medical need Dosing of the first patient in the ACESOT-1051 study represent...
ATRN-119 is the first and only macrocyclic ATR inhibitor in the clinic, with best in class potential On track to complete dose escalation in ABOYA-119 clinical trial and potentially generate initial human efficacy data in 2H 2024 Through the first 5 cohorts, ATRN-119 has been fo...